Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.81 |
| ▸ | CDC7 | O00311 | 1/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.81 |
| ▸ | AURKA | O14965 | 1/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.81 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.81 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.81 |
| ▸ | RAF1 | P04049 | 1/20 | 0.81 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.81 |
| ▸ | INSR | P06213 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | FES | P07332 | 1/20 | 0.81 |
| ▸ | CSF1R | P07333 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 1/20 | 0.81 |
| ▸ | MET | P08581 | 1/20 | 0.81 |
| ▸ | ROS1 | P08922 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768035 | 0.91 | ROCK2 (0.83) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| Bay-549 SCHEMBL29431218 | 0.90 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| Bay-549 SCHEMBL4765314 | 0.90 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| Bay-549 SCHEMBL29783174 | 0.90 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL8283427 | 0.89 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL4772131 | 0.88 | ROCK2 (0.79) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL8283424 | 0.87 | ROCK2 (0.77) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL4775566 | 0.86 | ROCK2 (0.76) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL8322481 | 0.86 | ROCK2 (0.87) | ROCK2CYP3A4OPRK1CDC7CHEK1 | |
| SCHEMBL8324210 | 0.86 | ROCK2 (1.00) | ROCK2CYP3A4OPRK1CDC7CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329716-B2 | e.g. N4-{3-Fluoro-4-[(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}pyrimidine-2,4-diamine; cardiovascular disorders; lower the blood pressure, increase coronary-perfusion, relax vessels; antitumor agent, metastasis; side effect reduction | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1751153-B1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-06-12 | — | — | US | disclosed |
| EP-1751153-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139595-A1 | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors | TNK2, ROCK1, ROCK2 | ROCK2 3/4885CYP3A4 1539/4885OPRK1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.